Stock screenerAll disclosures →
EDGAR →
INBX
Conviction 100HealthcareScan · Tue, Sep 8, 2026Hanging man
INBX$114.78-5.27%
ResistanceSupportVol 14Vol MA14 442.65K
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
Price114.78
Change-5.27%
Gap-3.91%
Rel volume8.40×
Avg volume383.9K
Avg $ vol42.89M
SMA 20110.09
SMA 5097.59
SMA 20089.15
Price vs 50+17.61%
Price vs 200+28.75%
MA stackbullish
50/200 cross—
Supertrendup · 101.16
RSI (14)57
MACD hist0.23
MACD cross—
Stoch %K / %D56 / 71
ADX (14)28
+DI / −DI22 / 31
RSI divergence—
MACD divergence—
ATR %+7.55%
ADR %7.93%
52w high141.84
52w low26.54
From 52w high-19.08%
Above 52w low+332.56%
New 52w highNo
SqueezeOff
Bollinger width49.32%
%B0.59
Donchian pos64.68%
Donchian high131.01
Donchian low85.06
AVWAP (52w high)107.86
vs AVWAP high+6.42%
AVWAP (52w low)86.57
vs AVWAP low+32.58%
OBV trendDown
Chaikin MF (20)0.38
Today vs 20d8.40×
Avg vol (14d)442.64K
Avg vol (20d)383.9K
Avg $ vol (20d)42.89M
Market cap1.69B
RS 3m (vs SPY)+34.83%
RS 6m (vs SPY)+60.60%
RS line new highNo
Trend template8/8
Technical rank87.3
1 week-9.41%
1 month+29.46%
3 months+28.78%
6 months+59.73%
1 year+307.31%
YTD+52.96%
P/E-12.06
P/B-31.89
P/S—
P/FCF-13.01
EPS-9.04
Div yield—
ROE264.37%
ROA-90.81%
Debt/Eq-3.33
Current5.07
EV/EBITDA-13.07
Gross margin—
Net margin—
Rev growth550.00%
EPS growth-108.30%
Price target266.67
Target upside132.33%
Analyst ratingBuy
Institutional101.89%
Ent. value1.73B
Revenue0
Net income-36.65M
Gross profit—
Free cash flow-129.82M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out14.67M
Employees110
ListedTue, May 28, 2024
Free float7.71M
Float %53.0%
Short interest3.22M
Days to cover14.4d
Short volume73.2%
Squeeze score100 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$2.34 vs −$2.50
Last surprise+6.4% beat
Setup gradeA+
Conviction100 / 100
Pattern quality—
Tech rank87.3 / 100
Group rank96 / 100 · Leading
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmHanging man
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC StudyYahoo Finance · Tue, Sep 8, 2026
- Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC StudyYahoo Finance · Fri, Sep 4, 2026
- Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC StudyPR Newswire · Fri, Sep 4, 2026
Congress activity
Disclosed STOCK Act trades in INBX
No recent disclosed trades by Congress in INBX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in INBX · 5 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
MANHARD KIMBERLY Director · Stock Option (right to buy) · 2026-06-03 | Grant | 15K | $0 | 2026-06-03 | 2026-06-04 |
Kayyem Jon Faiz Director · Stock Option (right to buy) · 2026-06-03 | Grant | 15K | $0 | 2026-06-03 | 2026-06-04 |
Vuori Kristiina MD Director · Stock Option (right to buy) · 2026-06-03 | Grant | 15K | $0 | 2026-06-03 | 2026-06-04 |
FORSYTH DOUGLAS Director · Stock Option (right to buy) · 2026-06-03 | Grant | 15K | $0 | 2026-06-03 | 2026-06-04 |
Matly David President · Stock Option (right to buy) · 2026-04-24 | Grant | 50K | $0 | 2026-04-24 | 2026-04-27 |
SEC filings
EDGAR filings in INBX · 9 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.